Dakota Wealth Management raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,620 shares of the medical equipment provider’s stock after purchasing an additional 122 shares during the period. Dakota Wealth Management’s holdings in Zimmer Biomet were worth $1,016,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Dunhill Financial LLC grew its stake in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $28,000. Bangor Savings Bank bought a new position in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet in the 3rd quarter valued at $35,000. Finally, Quarry LP acquired a new position in Zimmer Biomet in the 2nd quarter valued at $53,000. 88.89% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ZBH. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday. Barclays decreased their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James reduced their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, Oppenheimer dropped their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $124.11.
Zimmer Biomet Stock Down 0.2 %
Shares of NYSE:ZBH opened at $110.78 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The company has a market capitalization of $22.05 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a fifty day moving average of $107.89 and a 200-day moving average of $108.09.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the prior year, the firm earned $1.65 EPS. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.
Zimmer Biomet Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
- Five stocks we like better than Zimmer Biomet
- How to Buy Cheap Stocks Step by Step
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Where to Find Earnings Call Transcripts
- Despite Short-Term Risks Freeport McMoran Worth a Look
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.